Barinthus Biotherapeutics (BRNS) Projected to Post Quarterly Earnings on Thursday

Barinthus Biotherapeutics (NASDAQ:BRNS) is anticipated to post its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect Barinthus Biotherapeutics to post earnings of ($0.40) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 20, 2026 at 3:00 AM ET.

Barinthus Biotherapeutics Trading Up 4.4%

BRNS opened at $0.59 on Thursday. The company has a fifty day moving average price of $0.68 and a two-hundred day moving average price of $0.92. Barinthus Biotherapeutics has a 1-year low of $0.56 and a 1-year high of $2.92. The company has a market cap of $24.09 million, a P/E ratio of -0.31 and a beta of -0.63.

Hedge Funds Weigh In On Barinthus Biotherapeutics

An institutional investor recently raised its position in Barinthus Biotherapeutics stock. Baird Financial Group Inc. lifted its position in shares of Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) by 108.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 192,461 shares of the company’s stock after purchasing an additional 100,000 shares during the period. Baird Financial Group Inc. owned 0.48% of Barinthus Biotherapeutics worth $179,000 at the end of the most recent quarter. Institutional investors own 25.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on BRNS shares. HC Wainwright upped their price target on Barinthus Biotherapeutics from $3.00 to $4.00 and gave the stock a “buy” rating in a research note on Monday, November 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Barinthus Biotherapeutics in a report on Monday, December 22nd. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $4.00.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.